Session (CTI)

Standard approaches to measuring value in health technology assessment (HTA) have largely relied on incremental costs and benefits within the healthcare sector. There is growing interest internationally in whether these approaches adequately capture the full range of benefits for population health. Broader perspectives and value elements, such as transmission effects, productivity impacts, and improvements in adherence are among the additional elements that have been proposed as candidates for inclusion in HTA value frameworks.
Whether they belong, and under what conditions, are complex questions, and have recently been discussed in relation to recent methodological discussions on broader value elements in HTA. For some therapeutic areas, including infectious diseases where population-level prevention effects are material, or treatments where mode of administration has consequences for adherence and long-term outcomes, the limitations of conventional approaches are particularly apparent.
This session will examine which extensions to existing value frameworks have sufficient methodological grounding to support their increased consideration in submissions, where important uncertainties remain, and what the evidence shows about the impact on decision making of considering broader value. The discussion will also consider recent developments in HTA processes, including the exploration of broader or societal perspectives in some jurisdictions, and the implications of these developments across markets.
Ultimately, the session will explore how HTA frameworks may evolve to more comprehensively capture value for patients, populations, and health systems, and the potential implications for decision-making.
Sponsored by ViiV Healthcare